For clinical or commercial scale manufacturing in the pharmaceutical and biotech industries, just finding the right data to analyze can consume.
Janice-abel
Industrial-internet
Bristol-myers-squibb
03.09.21 Incorporating Excipients Into QbD Studies For Drug Development An Introduction
Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs.
Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more!
By Brian Carlin (DFE Pharma), Chris Moreton (FinnBrit Consulting), Dave Schoneker (Black Diamond Consulting), Katherine Ulman (KLU Consulting), and Joseph Zeleznik (IMCD)
This article is the first in a three-part series based on information from the new guide, “Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design,” published by the International Pharmaceutical Excipients Council Federation. Topics covered include measuring the impact of excipient variabili
Jens-christoph-matuszczyk
Pim-hermans
Elina-klijs
Alex-armengol
Kevin-sleijpen
James-faust
Anja-overweel
Melisa-carpio
Robert-smith
Gerhard-greller
Frank-detmers
Janice-abel